 |
|
Pallidal vs Subthalamic Deep Brain Stimulation for Parkinson Disease: Winner and Loser or a Sharing of Honors?
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
The delightfully illustrated and timely editorial1 on the "rematch" between globus pallidus interna (GPi) and subthalamic nucleus (STN) deep brain stimulation (DBS) in Parkinson disease was of special interest to our group, which just published a further contribution on this issue based on a nonrandomized study.2 The confirmation by Anderson and colleagues,3 in the only randomized, blinded comparative study to date, that STN and GPi DBS are equally effective in relieving motor symptoms and levodopa-induced dyskinesia at 1 year challenges the widely held assumption that STN is a superior target. They observed greater improvements in bradykinesia and higher levodopa dose reduction in their STN group but without significance (P>.05). These results require confirmation in wider studies over a longer term.
In an open study with similar sample size and follow-up, we also found no differences in main clinical variables between targets, although the greater percentage reduction of levodopa . . . [Full Text of this Article] AUTHOR INFORMATION
Adolfo Minguez-Castellanos, MD, PhD;
Francisco Escamilla-Sevilla, MD, PhD
RELATED ARTICLES
Pallidal vs Subthalamic Deep Brain Stimulation for Parkinson Disease: Winner and Loser or a Sharing of Honors?—Reply
Penelope Hogarth, Valerie Anderson, and John Hammerstad
Arch Neurol. 2005;62(10):1643.
EXTRACT
| FULL TEXT
Subthalamic Nucleus vs Globus Pallidus Interna Deep Brain Stimulation, the Rematch: Will Pallidal Deep Brain Stimulation Make a Triumphant Return?
Michael S. Okun and Kelly D. Foote
Arch Neurol. 2005;62(4):533-536.
EXTRACT
| FULL TEXT
|
